Compare Stocks: PVLA, PRAX, IONS, and SYRE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$42.38 -3.0%	$52.72	$42.36 ▼ $86.74	$7.04B	0.38	2.66 million shs	2.98 million shs
PRAX Praxis Precision Medicines	$243.34 -3.2%	$329.44	$50.56 ▼ $392.70	$6.79B	2.79	464,382 shs	622,135 shs
PVLA Palvella Therapeutics	$128.51 -4.4%	$147.86	$68.96 ▼ $161.38	$1.85B	-0.27	260,836 shs	215,835 shs
SYRE Spyre Therapeutics	$80.45 -6.3%	$93.96	$18.71 ▼ $110.18	$8.20B	3.1	1.14 million shs	1.44 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-3.56%	+0.39%	-19.44%	-20.50%	-37.59%
PRAX Praxis Precision Medicines	-3.26%	-11.35%	-24.87%	-23.28%	+371.99%
PVLA Palvella Therapeutics	-3.16%	+1.68%	-10.49%	-10.22%	+92.25%
SYRE Spyre Therapeutics	+0.25%	-7.36%	-5.19%	-13.19%	+348.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$42.38 -3.0%	$52.72	$42.36 ▼ $86.74	$7.04B	0.38	2.66 million shs	2.98 million shs
PRAX Praxis Precision Medicines	$243.34 -3.2%	$329.44	$50.56 ▼ $392.70	$6.79B	2.79	464,382 shs	622,135 shs
PVLA Palvella Therapeutics	$128.51 -4.4%	$147.86	$68.96 ▼ $161.38	$1.85B	-0.27	260,836 shs	215,835 shs
SYRE Spyre Therapeutics	$80.45 -6.3%	$93.96	$18.71 ▼ $110.18	$8.20B	3.1	1.14 million shs	1.44 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-3.56%	+0.39%	-19.44%	-20.50%	-37.59%
PRAX Praxis Precision Medicines	-3.26%	-11.35%	-24.87%	-23.28%	+371.99%
PVLA Palvella Therapeutics	-3.16%	+1.68%	-10.49%	-10.22%	+92.25%
SYRE Spyre Therapeutics	+0.25%	-7.36%	-5.19%	-13.19%	+348.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	110.48% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$613.26	152.02% Upside
PVLA Palvella Therapeutics	2.93	Moderate Buy	$207.43	61.41% Upside
SYRE Spyre Therapeutics	2.88	Moderate Buy	$110.40	37.23% Upside

Current Analyst Ratings Breakdown

Latest PVLA, PRAX, IONS, and SYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$270.00 ➝ $246.00
10/11/2026	SYRE Spyre Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$120.00
10/6/2026	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,201.00
10/6/2026	PRAX Praxis Precision Medicines	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$810.00 ➝ $826.00
10/1/2026	SYRE Spyre Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$121.00
10/1/2026	SYRE Spyre Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$110.00
9/25/2026	PVLA Palvella Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/24/2026	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,201.00
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$85.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$100.00
9/24/2026	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$582.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IONS Ionis Pharmaceuticals	$874.09M	8.06	N/A	N/A	$3.02 per share	14.03
PRAX Praxis Precision Medicines	$8.55M	794.63	N/A	N/A	$34.85 per share	6.98
PVLA Palvella Therapeutics	$42.81M	43.26	N/A	N/A	$2.36 per share	54.45
SYRE Spyre Therapeutics	$890K	9,211.98	N/A	N/A	$7.21 per share	11.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	11/10/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest PVLA, PRAX, IONS, and SYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	PVLA Palvella Therapeutics	-$1.7960	N/A	N/A	N/A	$0.02 million	N/A
11/9/2026	Q3 2026	PRAX Praxis Precision Medicines	-$3.53	N/A	N/A	N/A	$0.13 million	N/A
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.21	N/A	N/A	N/A	$182.98 million	N/A
11/3/2026	Q3 2026	SYRE Spyre Therapeutics	-$0.79	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
PRAX Praxis Precision Medicines	N/A	15.73	15.73
PVLA Palvella Therapeutics	N/A	21.18	21.18
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IONS Ionis Pharmaceuticals	93.86%
PRAX Praxis Precision Medicines	67.84%
PVLA Palvella Therapeutics	40.11%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
IONS Ionis Pharmaceuticals	1.81%
PRAX Praxis Precision Medicines	3.00%
PVLA Palvella Therapeutics	17.20%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
PRAX Praxis Precision Medicines	168	27.92 million	27.08 million	Optionable
PVLA Palvella Therapeutics	29	14.41 million	11.93 million	N/A
SYRE Spyre Therapeutics	112	101.91 million	85.92 million	Optionable

PVLA, PRAX, IONS, and SYRE Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Target Price of $109.71 According to Analysts

October 10 at 4:28 AM | marketbeat.com

Spyre Therapeutics Announces $350 Million Public Stock Offering Priced at $85 Per Share

October 9, 2026 | kalkinemedia.comK

Spyre Therapeutics (NASDAQ:SYRE) Stock Jumps 7.3% - Here's What Happened

October 9, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering

October 8, 2026 | finance.yahoo.com

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - October 5, 2026

October 6, 2026 | biospace.comB

Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market

October 6, 2026 | finance.yahoo.com

Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell

October 6, 2026 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Stock Falls 12.7% - Should You Sell?

October 6, 2026 | marketbeat.com

Spyre Therapeutics Prices $350 Mln Public Offering Of Shares

October 6, 2026 | rttnews.com

Spyre Therapeutics prices $350M public offering at $85 per share

October 6, 2026 | msn.com

Spyre Therapeutics Commences Public Offering of Common Stock

October 5, 2026 | finance.yahoo.com

Spyre Therapeutics stock falls on public offering launch

October 5, 2026 | finance.yahoo.com

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

October 5, 2026 | globenewswire.com

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

October 5, 2026 | globenewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards - October 2, 2026

October 5, 2026 | biospace.comB

Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

October 4, 2026 | theglobeandmail.com

Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale

October 4, 2026 | defenseworld.netD

Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares of Stock

October 3, 2026 | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Stock: Insider Scott Burrows Sells 7,500 Shares

October 3, 2026 | insidertrades.com

Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 17,500 Shares of Stock

October 3, 2026 | americanbankingnews.com

Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 28,933 Shares of Stock

October 3, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PVLA, PRAX, IONS, and SYRE Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

$42.38 -1.29 (-2.95%)

Closing price 04:00 PM Eastern

Extended Trading

$42.54 +0.15 (+0.37%)

As of 05:27 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Praxis Precision Medicines NASDAQ:PRAX

$243.34 -8.04 (-3.20%)

Closing price 04:00 PM Eastern

Extended Trading

$247.79 +4.45 (+1.83%)

As of 05:18 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$128.51 -5.87 (-4.37%)

Closing price 04:00 PM Eastern

Extended Trading

$128.63 +0.12 (+0.09%)

As of 04:10 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Spyre Therapeutics NASDAQ:SYRE

$80.45 -5.45 (-6.34%)

Closing price 04:00 PM Eastern

Extended Trading

$80.54 +0.09 (+0.12%)

As of 04:56 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, PRAX, IONS, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, PRAX, IONS, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, PRAX, IONS, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PVLA, PRAX, IONS, and SYRE Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Praxis Precision Medicines NASDAQ:PRAX

Palvella Therapeutics NASDAQ:PVLA

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PVLA, PRAX, IONS, and SYRE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PVLA, PRAX, IONS, and SYRE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PVLA, PRAX, IONS, and SYRE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PVLA, PRAX, IONS, and SYRE Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Praxis Precision Medicines NASDAQ:PRAX

Palvella Therapeutics NASDAQ:PVLA

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools